Drug Trial Radar · NCT06189963
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 21, 2023
Primary completion
Mar 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Conditions
- Moderate Alzheimer Disease
Interventions
SNK01Biological
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
PlaceboOther
Sodium Lactate Hartmann's Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicityTime frame: 3 weeks
- Maximum tolerated dose determinationTime frame: 3 weeks
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 1 Year
- Preliminary efficacy in cognitive assessment scores of CDR-SBTime frame: 1 Year
- Preliminary efficacy in cognitive assessment scores of MMSETime frame: 1 Year
- Preliminary efficacy in cognitive assessment scores of NPITime frame: 1 Year
- Preliminary efficacy in cognitive assessment scores of ADCS-ADL-SevereTime frame: 1 Year
- Preliminary efficacy in cognitive assessment scores of ADAS-CogTime frame: 1 Year
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Behavioral Research Specialists, LLC
Glendale, California · Recruiting
Syrentis Clinical Research
Santa Ana, California · Recruiting
Valiance Clinical Research
Tarzana, California · Withdrawn
K2 Medical Research
Maitland, Florida · Recruiting
AdventHealth Research Institute
Orlando, Florida · Recruiting
Rutgers Health
Newark, New Jersey · Recruiting
Alzheimer's Disease Research Center
Albany, New York · Recruiting
Ottawa Memory Clinic
Ottawa, Ontario, Canada · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.